カテゴリ： GlobalData, アメリカ, 企業調査

Cytodyn Inc (CYDY)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Cytodyn Inc (CYDY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7984
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：73
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Cytodyn Inc (Cytodyn) is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies t for the treatment of Human Immunodeficiency Virus (HIV) infections. The company’s products pipeline include PRO 140, Cytofeline and Cytolin. Cytodyn’s PRO 140 is a viral-entry inhibitor intended to protect healthy cells from viral infection which blocks the HIV co-receptor C-C chemokine receptor type 5 (CCR5) on T-cells. Cytofeline, a anti-LFA-1 antibody is used for the treatment of FIV infection. Cytolin is a mouse monoclonal antibody developed to identify a immune cell called cytotoxic T cell (CTL). Cytodyn is headquartered in Vancouver, Washington, the US.

Cytodyn Inc (CYDY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytodyn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Cytodyn Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 12
Venture Financing 14
ProstaGene Raises USD0.4 Million in Financing 14
Cytodyn Raises USD2.7 million in Financing Round 15
CytoDyn Raises USD3.3 million in Venture Financing Round 16
ProstaGene Raises USD0.4 Million in Venture Financing 17
Partnerships 18
CytoDyn Amends Research Agreement with Drexel University College of Medicine 18
Licensing Agreements 19
CytoDyn Enters into Licensing Agreement with Lonza Sales 19
Equity Offering 20
CytoDyn Files Registration Statement for Public Offering of Shares for USD55 Million 20
CytoDyn Plans to Raise up to USD200 Million in Public Offering of Securities 21
CytoDyn Raises USD4.3 Million in Private Placement of Shares and Warrants 22
CytoDyn Raises USD1.2 Million in Private Placement of Shares 23
CytoDyn Raises USD10 Million in Private Placement of Shares and Warrants 24
CytoDyn Raises USD4.3 Million in Private Placement of Shares 25
CytoDyn Raises USD7.3 Million in Private Placement of Shares 26
CytoDyn Completes Final Tranche Of Private Placement Of Units For US$6.7 Million 27
CytoDyn Raises USD14.5 Million in Private Placement of Units 28
CytoDyn Completes Private Placement Of Shares For US$0.6 Million 29
Debt Offering 30
CytoDyn Raises USD0.6 Million in Private Placement of Convertible Notes 30
CytoDyn Raises USD1.2 Million in Private Placement of 5% Notes 31
CytoDyn Raises USD0.2 Million in Private Placement of Convertible Notes 32
Cytodyn Completes Private Placement Of Notes For US$3.7 Million 33
Acquisition 34
CytoDyn to Acquires ProstaGene 34
Cytodyn Inc – Key Competitors 35
Cytodyn Inc – Key Employees 36
Cytodyn Inc – Locations And Subsidiaries 37
Head Office 37
Other Locations & Subsidiaries 37
Recent Developments 38
Corporate Communications 38
Jan 30, 2017: CytoDyn appoints executive chairman 38
Jan 30, 2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 39
Product News 40
12/07/2017: Independent Data Monitoring Committee Recommends Continuation of CytoDyn’s PRO 140 Pivotal Combination Therapy Trial as Planned Without Modifications to Achieve Primary Endpoint 40
08/21/2017: CytoDyn Provides Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV 41
08/09/2017: CytoDyn Provides Update on Enrollment in its Pivotal Phase 2b/3 HIV Combination Trial 42
07/12/2018: CytoDyn to Expand Strategic Focus with PRO 140 to Cancer and Immunologic Disorders 43
07/12/2018: CytoDyn Announces Leadership Changes to Align with Expanded Focus of PRO 140 to Cancer and Immunological Disorders 45
06/11/2018: CytoDyn ASM Poster Presentation June 9, 2018, at ASM Microbe 2018, Atlanta, GA 47
06/09/2018: Weekly Injections of CytoDyns PRO 140 in Combination with Optimized Antiretroviral Treatment Shows Long-Acting HIV-1 Viral Suppression 48
06/04/2018: Results from CytoDyn’s Pivotal PRO 140 Combination Therapy Trial in HIV to be Presented at ASM Microbe 2018 on June 9 49
06/01/2017: CytoDyn to Present an Update on its PRO 140 Pivotal Phase 2b/3 Study in Treatment-Experienced HIV-1 Patients at ASM Microbe 2017 50
04/11/2018: CytoDyn to Present Primary Efficacy Endpoint Results from its PRO 140 Pivotal Trial in Late-Breaking Session at ASM Microbe 2018 51
04/11/2017: CytoDyn Appoints Scott A. Kelly, M.D. to Its Board of Directors 52
03/29/2018: CytoDyn Forms Scientific Advisory Board to Advance PRO 140 Development in Immunological Disorders 53
02/20/2018: CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection 54
01/30/2017: CytoDyn Strengthens Executive Management With Appointment of Anthony D. Caracciolo as Executive Chairman 56
Product Approvals 57
Jun 22, 2018: CytoDyn Announces Productive Pre-BLA Meeting with FDA for PRO 140 Combination Therapy 57
Mar 14, 2018: CytoDyn to Amend Protocol for PRO 140 Phase 2 Trial in GvHD 58
Oct 13, 2017: CytoDyn Provides Update on PRO 140 Combination Therapy Pivotal Trial in HIV Patients Following Constructive Meeting With FDA 59
Oct 05, 2017: CytoDyn Receives Orphan Drug Designation for PRO 140 for Prevention of Graft Versus Host Disease 60
Sep 06, 2017: CytoDyn Provides Further Update on PRO 140 Pivotal Combination Therapy Trial in Patients with HIV 61
Apr 17, 2017: Potential for CytoDyn’s PRO 140 for Treating HIV Patients Deemed Too Broad for Orphan Drug Designation by the FDA 62
Jan 11, 2017: CytoDyn Files for Breakthrough Therapy Designation With the FDA for PRO 140 in HIV Therapy 63
Clinical Trials 64
Jul 30, 2018: Cytodyn announces significantly improved response rate at higher dose of PRO 140 in HIV phase 3 monotherapy trial 64
Jul 16, 2018: CytoDyn Announces Positive Results from Completed Pivotal PRO 140 HIV Combination Trial 66
Jun 26, 2018: New Research Supports Potential for CytoDyn’s PRO 140 to Inhibit Breast Cancer Metastasis 67
Jun 20, 2018: CytoDyn Provides Update on Phase 2 Clinical Trial with PRO 140 in GvHD 68
May 24, 2018: Results of CytoDyns PRO 140 CD01 Trial and Extension Study Published in HIV Clinical Trials 69
Nov 14, 2017: CytoDyn’s PRO 140 Monoclonal Antibody Prevents Graft-Versus-Host Disease in Model of Bone Marrow Stem Cell Transplantation 70
May 17, 2017: CytoDyn Treats First Patient with PRO 140 in Phase 2 Trial for Graft versus Host Disease 71
Feb 14, 2017: Two-Year Update From CytoDyn’s PRO 140 Monotherapy Study in HIV to be Featured in Two Events at CROI 2017 72
Appendix 73
Methodology 73
About GlobalData 73
Contact Us 73
Disclaimer 73

List of Tables
Cytodyn Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytodyn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytodyn Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
CytoDyn Completes Acquisition Of PRO 140 From Progenics Pharma 12
ProstaGene Raises USD0.4 Million in Financing 14
Cytodyn Raises USD2.7 million in Financing Round 15
CytoDyn Raises USD3.3 million in Venture Financing Round 16
ProstaGene Raises USD0.4 Million in Venture Financing 17
CytoDyn Amends Research Agreement with Drexel University College of Medicine 18
CytoDyn Enters into Licensing Agreement with Lonza Sales 19
CytoDyn Files Registration Statement for Public Offering of Shares for USD55 Million 20
CytoDyn Plans to Raise up to USD200 Million in Public Offering of Securities 21
CytoDyn Raises USD4.3 Million in Private Placement of Shares and Warrants 22
CytoDyn Raises USD1.2 Million in Private Placement of Shares 23
CytoDyn Raises USD10 Million in Private Placement of Shares and Warrants 24
CytoDyn Raises USD4.3 Million in Private Placement of Shares 25
CytoDyn Raises USD7.3 Million in Private Placement of Shares 26
CytoDyn Completes Final Tranche Of Private Placement Of Units For US$6.7 Million 27
CytoDyn Raises USD14.5 Million in Private Placement of Units 28
CytoDyn Completes Private Placement Of Shares For US$0.6 Million 29
CytoDyn Raises USD0.6 Million in Private Placement of Convertible Notes 30
CytoDyn Raises USD1.2 Million in Private Placement of 5% Notes 31
CytoDyn Raises USD0.2 Million in Private Placement of Convertible Notes 32
Cytodyn Completes Private Placement Of Notes For US$3.7 Million 33
CytoDyn to Acquires ProstaGene 34
Cytodyn Inc, Key Competitors 35
Cytodyn Inc, Key Employees 36
Cytodyn Inc, Subsidiaries 37

List of Figures
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Cytodyn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Cytodyn Inc, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Cytodyn Inc (CYDY)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Queen’s University Belfast：製薬・医療：M&Aディール及び事業提携情報
    Summary Queen's University Belfast (Queen’s University) is an educational institution that offers education and research services. The institute provides undergraduate, professional development and postgraduate programs. Its postgraduate programs comprise postgraduate diploma in nursing, MSc advance …
  • American Water Works Co Inc (AWK)：企業の財務・戦略的SWOT分析
    Summary American Water Works Co Inc (AWW) is a utility company that offers fire protection and sanitation services. The company's services include water and wastewater services, military services, municipal and industrial contract, residual and home owner services. Its home owner services include wa …
  • Carl Zeiss AG：企業の戦略的SWOT分析
    Carl Zeiss AG - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • The Greenbrier Companies Inc：企業の戦略・SWOT・財務情報
    The Greenbrier Companies Inc - Strategy, SWOT and Corporate Finance Report Summary The Greenbrier Companies Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • OncoSil Medical Ltd (OSL)-製薬・医療分野：企業M&A・提携分析
    Summary OncoSil Medical Ltd (OncoSil), formerly NeuroDiscovery Ltd is a medical device company that develops and commercializes treatments for patients with pancreatic and liver cancer. The company’s lead product include oncosil, a brachytherapy device that emits beta radiation and is implanted dire …
  • E.ON UK Plc：発電所・企業SWOT分析
    E.ON UK Plc - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (execut …
  • Emera (Caribbean) Inc.：企業の戦略的SWOT分析
    Emera (Caribbean) Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • EDF Energy Holdings Ltd：企業の発電所・SWOT分析2018
    EDF Energy Holdings Ltd - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key emplo …
  • Kimco Realty Corporation：企業の戦略・SWOT・財務情報
    Kimco Realty Corporation - Strategy, SWOT and Corporate Finance Report Summary Kimco Realty Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Jersey Oil and Gas Plc (JOG)：企業の財務・戦略的SWOT分析
    Summary Jersey Oil and Gas Plc (Jersey Oil), formerly Trap Oil Group Plc is an upstream oil and gas exploration and production company. The company acquires, explores, develops and produces natural gas properties in the UK continental shelf. Its oil and gas properties include Homer Block, Cortina Bl …
  • Micropos Medical AB (MPOS)：医療機器：M&Aディール及び事業提携情報
    Summary Micropos Medical AB (Micropos Medical) is a medical device company. The company develops technologies that enhance the precision in radiotherapy of cancer including hypofractionation and stereotactic radio surgery (SRS) and stereotactic body radiotherapy (SBRT). Its products include RayPilot …
  • Visteon Corporation：企業のM&A・事業提携・投資動向
    Visteon Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Visteon Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Capitol Health Ltd (CAJ)：企業の財務・戦略的SWOT分析
    Summary Capitol Health Ltd (Capitol Health) is a diagnostic imaging service provider. The company offers services such as bone densitomety, computer tomography, cone beam CT, CT angiography, doppler, echocardiography, fluoroscopy, general X-ray, magnetic resonance imaging, mammography, nuclear medic …
  • Tetra Pak International SA：企業の戦略的SWOT分析
    Tetra Pak International SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Coloplast AS (COLO B)：企業の財務・戦略的SWOT分析
    Coloplast AS (COLO B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Petro Vista Energy Corp (PTV.H)：石油・ガス：M&Aディール及び事業提携情報
    Summary Petro Vista Energy Corp (Petro Vista) is an oil and gas company that offers oil and gas exploration and development services. The company offers acquisition, development, exploration, and production of oil and gas properties. It offers upstream oil and gas services with exploration and produ …
  • LifePoint Health：企業の戦略・SWOT・財務情報
    LifePoint Health - Strategy, SWOT and Corporate Finance Report Summary LifePoint Health - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Richard Wolf GmbH：企業の戦略的SWOT分析
    Richard Wolf GmbH - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Landis+Gyr AG-エネルギー分野：企業M&A・提携分析
    Summary Landis+Gyr AG (Landis+Gyr) is an integrated energy management company that provide end-to-end advanced metering solutions. It delivers comprehensive services including cloud services, managed services, smart grid services, software services, solutions consulting and support services. The com …
  • Bank of America Corporation：企業のM&A・事業提携・投資動向
    Bank of America Corporation - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of America Corporation Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acq …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆